Hence, it is reasonable to assume that downregulation of ATX and LPAR2 is an additional mechanism underlying the anticancer effect of NSAIDs, at least in certain cancer types in which LPAR2 is upregulated, such as colorectal cancer [31, 34]. The gene discussed is ENPP2; the disease is colorectal cancer.